Self-sealing sclera crosslinking device

Abstract

The utility model relates to the technical field of medical instruments, in particular to a self-sealing sclera cross-linking device which comprises a device body, the device body comprises an attaching face used for being attached to a rear sclera, and the attaching face is an arc-shaped curved face bent inwards; the device body comprises a cavity with openings in the two ends, and a first opening of the cavity is located in the binding face; a light reflecting part is arranged in the second opening of the cavity, and the light reflecting part, the cavity and the posterior sclera define a closed treatment cavity; the cross-linking substance enters the treatment cavity to be cross-linked with the posterior sclera; the first opening of the cavity is provided with an inflatable annular sealing ring on the binding face, and the annular sealing ring is used for being attached to the posterior sclera and expanding during inflation so as to fix the sclera cross-linking device between the posterior sclera and tissue behind the posterior sclera. According to the self-sealing sclera cross-linking device, the inflatable annular sealing ring is arranged, so that the sclera cross-linking device can be clamped between a posterior sclera and tissue behind the posterior sclera, and fixation is achieved.

Description

Technical Field

[0001] This utility model relates to the field of medical device technology, and in particular to a self-sealing scleral crosslinking device. Background Technology

[0002] Based on refractive components, myopia can be classified into refractive myopia and axial myopia. Axial myopia is caused by the continuous elongation of the eyeball. When the eyeball grows to a certain extent, the various layers of the eyeball wall (retina, choroid, sclera) become thinner, making it prone to various pathological changes and leading to a series of complications, including retinal detachment, retinal schisis, myopic macular degeneration, and choroidal atrophy, which can even cause blindness in severe cases. The main structure of the sclera is the stroma, which is composed of collagen fibers. Through the cross-linking action of ultraviolet light and the photosensitizer riboflavin, the cross-linked collagen fibers can become more robust, thereby increasing the biomechanical strength of the sclera. Therefore, scleral cross-linking technology can increase the rigidity of the posterior pole of the sclera, thereby controlling the elongation of the eyeball and preventing myopia.

[0003] However, traditional scleral crosslinking devices mostly use negative pressure to fix them to the scleral surface. During this process, oxygen needs to be continuously applied into the negative pressure chamber to ensure the biological activity of the sclera. This makes it difficult to effectively control the negative pressure in the chamber and poses a risk of detachment.

[0004] Therefore, existing technologies urgently need improvement. Utility Model Content

[0005] To address the aforementioned technical problems, this utility model proposes a self-sealing scleral crosslinking device.

[0006] The present invention discloses a self-sealing scleral crosslinking device, the scleral crosslinking device comprising:

[0007] The device body includes an adhesion surface for applying to the sclera, the adhesion surface being an inwardly curved arc surface;

[0008] The device body includes a cavity with openings at both ends. The first opening of the cavity is located on the bonding surface. A reflective part is provided in the second opening of the cavity. The reflective part, the cavity, and the posterior sclera form a closed treatment cavity. The cross-linking substance enters the treatment cavity through the device body and cross-links with the posterior sclera.

[0009] The first opening of the cavity is provided with an inflatable annular sealing ring on the bonding surface. The annular sealing ring is used to bond with the posterior sclera and to expand when inflated to fix the scleral crosslinking device between the posterior sclera and the tissue behind the posterior sclera.

[0010] In some embodiments, the device body further includes an extension extending from the mating surface, the extension having a first channel, a second channel, a third channel and a fourth channel communicating with the cavity; wherein the fourth channel communicates with the annular sealing ring for inflating or deflating the annular sealing ring.

[0011] In some embodiments, the scleral crosslinking device further includes:

[0012] The drug application port and the recovery port are disposed on the inner side of the cavity. The recovery port is disposed at the lowest point of the liquid level in the cavity after the scleral cross-linking device is fixed to the posterior sclera. The drug application port and the recovery port are disposed opposite to each other.

[0013] The first channel is in airtight communication with the drug delivery port for introducing substances into the cavity; the second channel is used to guide light into the reflective part; the third channel is in airtight communication with the recovery port for discharging substances from the cavity.

[0014] In some embodiments, the annular sealing ring is a hollow structure made of an elastic material; the elastic material is silicone.

[0015] In some embodiments, the annular sealing ring is a hollow, cylindrical structure.

[0016] In some embodiments, the annular sealing ring includes a first annular surface that adheres to the posterior sclera, a second annular surface that is fixed to the adhering surface, and two side surfaces that connect the first annular surface and the second annular surface. The first annular surface, the second annular surface, and the two side surfaces form a hollow structure. The first annular surface is a smooth surface, and the two side surfaces are wrinkled surfaces that can be compressed and unfolded.

[0017] In some embodiments, the shape of the drug delivery port on the inner wall of the cavity is selected from any one of a circular hole, an elliptical hole, or an elongated opening; the drug delivery port communicates with the first channel, and the other end of the first channel can communicate with an infusion device or with the outside world, for applying the substance into the cavity and communicating with the outside world to balance the air pressure in the cavity, the substance including at least one of the cross-linked substance and physiological saline, the cross-linked substance including at least one of dissolved oxygen riboflavin solution and oxygen.

[0018] In some embodiments, the shape of the recovery port is selected from any one of a circular hole, an elliptical hole, or an elongated opening; the recovery port is connected to the third channel, and the other end of the third channel can be connected to a pump or to the outside, for the purpose of extracting excess substances from the cavity and balancing the air pressure in the cavity by connecting to the outside; the substances include at least one of the cross-linked substance and physiological saline, and the cross-linked substance includes at least one of dissolved oxygen riboflavin solution and oxygen.

[0019] In some embodiments, when riboflavin solution or saline solution is injected into the cavity through the administration port, the recovery port is connected to the outside through the third channel to balance the pressure inside the cavity; when riboflavin solution or saline solution is withdrawn from the cavity through the recovery port, the administration port is connected to the outside through the first channel to balance the pressure inside the cavity.

[0020] In some embodiments, the drug delivery port is further covered with a shape memory alloy, one end of which is fixed to the wall of the cavity at the drug delivery port, and the other end of which is a free end;

[0021] When the light is turned off, the shape memory alloy undergoes thermal deformation and bends towards the radial center of the first opening of the cavity, thereby not blocking the drug delivery port, so that the drug delivery port can deliver substances into the cavity;

[0022] When the light is turned on, the shape memory alloy that has undergone thermal deformation cools down and returns to its original shape, covering the drug delivery port. This allows the shape memory alloy to seal the drug delivery port, preventing any remaining material in the first channel from entering the cavity and affecting the illumination.

[0023] By adopting the above technical solution, this utility model has at least the following beneficial effects:

[0024] This invention discloses a self-sealing scleral crosslinking device. An inflatable annular sealing ring is placed at the first opening of the cavity. When the scleral crosslinking device needs to be fixed to the posterior sclera, the annular sealing ring inflates, increasing the thickness of the cavity and allowing the device to be secured between the posterior sclera and the tissue behind it. This eliminates the need for negative pressure adsorption within the cavity, thus avoiding the problems of continuously applying oxygen and controlling negative pressure effectively. Attached Figure Description

[0025] To more clearly illustrate the technical solutions in the embodiments of this utility model or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this utility model. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0026] Figure 1 This is a schematic diagram of the structure of a self-sealing scleral crosslinking device according to an embodiment of the present invention;

[0027] Figure 2 This is a schematic diagram of the bonding between a self-sealing scleral crosslinking device and the posterior sclera according to an embodiment of the present invention.

[0028] Figure 3 This is a schematic diagram of the structure of the extension of a self-sealing scleral crosslinking device according to an embodiment of the present invention;

[0029] Figure 4 This is a schematic diagram of the structure of an annular sealing ring according to an embodiment of the present invention;

[0030] Figure 5 This is a schematic diagram of the structure of the annular sealing ring according to another embodiment of the present invention;

[0031] Figure 6 This is a schematic diagram of the shape memory alloy and the drug application port of the scleral crosslinking device according to an embodiment of the present invention.

[0032] [List of Labels in the Attached Image]

[0033] 1. Adhesive surface;

[0034] 2. Cavity; 201. First opening; 202. Second opening;

[0035] 301. Reflector; 302. Beam leveler; 303. High-transparency lens.

[0036] 4. Annular sealing ring; 401. First annular surface; 402. Second annular surface; 403. First corrugated side surface; 404. Second corrugated side surface;

[0037] 5. Extension section; 501. First channel; 502. Second channel; 503. Third channel; 504. Fourth channel;

[0038] 6. Drug application port; 8. Shape memory alloy; 9. Control circuit; 10. Posterior sclera. Detailed Implementation

[0039] To make the objectives, technical solutions, and advantages of this utility model clearer, the embodiments of this utility model will be further described in detail below with reference to specific examples and accompanying drawings.

[0040] It should be noted that all uses of "first" and "second" in the embodiments of this utility model are for the purpose of distinguishing two entities or parameters with the same name but different names. It is clear that "first" and "second" are only for the convenience of expression and should not be construed as limiting the embodiments of this utility model. Subsequent embodiments will not explain this in detail.

[0041] These embodiments are provided to make the disclosure thorough and complete, and to fully express the scope of the disclosure to those skilled in the art. It should be noted that, unless otherwise specifically stated, the relative arrangement of components and steps, material composition, numerical expressions, and values ​​set forth in these embodiments should be interpreted as exemplary only and not as limiting.

[0042] It should be noted that, in the description of this disclosure, unless otherwise stated, "a plurality of" means two or more; the terms "upper," "lower," "left," "right," "inner," and "outer," etc., indicating orientation or positional relationship, are only for the convenience of describing this disclosure and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as a limitation of this disclosure. When the absolute position of the described object changes, the relative positional relationship may also change accordingly.

[0043] like Figure 1-2 A self-sealing scleral crosslinking device according to an embodiment of the present invention is shown. The scleral crosslinking device includes: a device body adapted to the shape of the sclera, the device body including a bonding surface 1 for bonding the sclera 10 after bonding, the bonding surface 1 being an inwardly curved arc surface; the device body also includes an extension portion 5 extending from the bonding surface 1.

[0044] The device body includes a cavity 2 with openings at both ends. The first opening 201 of the cavity 2 is located on the mating surface 1. A reflective part is provided inside the second opening 202 of the cavity 2. The reflective part, the cavity 2, and the posterior sclera 10 form a closed treatment cavity. The first opening 201 and the second opening 202 are located at opposite ends of the cavity 2. The reflective part includes, in sequence from the second opening 202 to the first opening 201, a reflector 301, a light-diffusing plate 302, and a high-reflection lens 303. The reflector 301 is disposed on the inner bottom surface of the treatment cavity. The reflector 301 is preferably a high-reflection film. The reflector 301 is used to change the light path after receiving light, so that the reflected light perpendicularly illuminates the treatment area. In this invention, a light source can be provided through the channel described below (e.g., the second channel 502) to provide light to the reflector 301. The light source is preferably an optical fiber, and secondarily an LED light source. The number of optical fibers can be one or more, protruding from the inner wall of the cavity through the channel described below. The end section is set perpendicular to the center of the reflector 301. Using multiple optical fiber wires, one or several optical fibers can be lit as needed, thereby controlling the light intensity of the light source.

[0045] An inflatable annular sealing ring 4 is provided on the mating surface 1 of the first opening 201 of the cavity 2. The annular sealing ring 4 is used to fit against the posterior sclera 10 and to expand when inflated to fix the scleral crosslinking device between the posterior sclera 10 and the tissue behind the posterior sclera 10. By setting the inflatable annular sealing ring 4 on the first opening 201 of the cavity 2, when the scleral crosslinking device needs to be fixedly fitted to the posterior sclera 10, the annular sealing ring 4 expands when inflated, increasing the thickness of the cavity 2 position of the scleral crosslinking device. The scleral crosslinking device can then be secured between the posterior sclera 10 and the tissue behind the posterior sclera 10, thereby achieving fixation. Compared with the prior art, this utility model can achieve fixation of the scleral crosslinking device without negative pressure adsorption in the cavity 2, thus avoiding the problems of continuously applying oxygen into the negative pressure cavity and the difficulty in effectively controlling the negative pressure.

[0046] The annular sealing ring 4 is a hollow structure made of an elastic material. The elastic material is preferably a material that can expand upon inflation, specifically silicone, which satisfies biocompatibility. In other preferred embodiments, other inflatable elastic materials that meet biocompatibility requirements are also suitable for the annular sealing ring of this embodiment.

[0047] like Figure 4 In a preferred embodiment shown, the annular sealing ring 4 is a hollow structure in the shape of a circular tube. Figure 4 The circular cross-section of the annular sealing ring 4 shown represents the state of the annular sealing ring 4 after it has been inflated.

[0048] like Figure 5In another preferred embodiment shown, the annular sealing ring 4 includes a first annular surface 401 that conforms to the posterior sclera 10, a second annular surface 402 that is fixed to the conforming surface 1, and two side surfaces connecting the first annular surface 401 and the second annular surface 402. The first annular surface 401, the second annular surface 402, and the two side surfaces form a hollow structure. The first annular surface 401 is a smooth surface, and the two side surfaces are pleated surfaces that can be compressed and unfolded. The pleated surfaces can be two or more layers of pleats. Figure 5 The diagram shows two pleated surfaces, namely the first pleated side 403 and the second pleated side 404. When the annular sealing ring 4 is in the deflated and compressed state, the scleral cross-linking device is attached to the posterior sclera 10. Then, the annular sealing ring 4 is inflated. The pleated surface of the annular sealing ring 4 allows for a thicker annular sealing ring 4 after inflation. Alternatively, the inflation amount can be appropriately reduced when a thicker thickness is not required. This adjustable thickness of the annular sealing ring 4 makes the self-sealing performance of the scleral cross-linking device more versatile.

[0049] The inflation of the annular sealing ring 4 increases the thickness of the front end of the scleral cross-linking device, thereby fixing the eyeball. Deflating the ring during removal or insertion causes it to contract, facilitating the procedure. Furthermore, the annular sealing ring 4 effectively prevents riboflavin from contacting non-cross-linked areas, resulting in better treatment outcomes.

[0050] The application port 6 and the recovery port (not shown) are located on the inner side of the cavity 2. The recovery port is located at the lowest point of the liquid level in the cavity 2 after the scleral crosslinking device and the posterior sclera 10 are fixed (see [link to relevant documentation] for details). Figure 2 The application port 6 and the recovery port are positioned opposite each other. This positioning of the recovery port allows for better recovery of the liquid within chamber 2.

[0051] The administration port 6 is essentially the exit point of the administration channel. The recovery port is used to recover excess substances such as riboflavin solution or saline from the treatment cavity.

[0052] Figure 3 The extension 5 shown is provided with a first channel 501, a second channel 502, a third channel 503 and a fourth channel 504 that communicate with the cavity 2; wherein, the fourth channel 504 communicates with the annular sealing ring 4 for inflating or deflating the annular sealing ring 4.

[0053] The first channel 501 is airtightly connected to the drug application port 6 for introducing substances into the cavity 2;

[0054] The second channel 502 is used to guide light to the reflector; the second channel 502 can be an optical fiber.

[0055] The third channel 503 is airtightly connected to the recovery port and is used to discharge the material in the cavity 2.

[0056] Preferably, the shape of the drug application port 6 on the inner wall of the cavity 2 is selected from any one of a circular hole, an elliptical hole, or an elongated opening.

[0057] The drug delivery port 6 is connected to the first channel 501. The other end of the first channel 501 can be selectively connected to the delivery device or to the outside world for applying substances into the cavity 2 and for balancing the air pressure inside the cavity 2 by connecting to the outside world. The substances include at least one of a cross-linking substance and physiological saline; the cross-linking substance enters the treatment cavity through the device body and cross-links with the posterior sclera; the cross-linking substance includes at least one of dissolved oxygen riboflavin solution and oxygen.

[0058] Preferably, the shape of the recycling port is selected from any one of a circular hole, an elliptical hole, or an elongated opening.

[0059] The recovery port is connected to the third channel 503, the other end of which can be selectively connected to a pump or to the outside environment for extracting excess material from the cavity 2 and for balancing the air pressure within the cavity 2 by connecting to the outside environment. The material includes at least one of a cross-linking substance and physiological saline; the cross-linking substance enters the treatment cavity through the device body and cross-links with the posterior sclera; the cross-linking substance includes at least one of dissolved oxygen riboflavin solution and oxygen.

[0060] When riboflavin solution or saline solution is injected into cavity 2 through injection port 6, the recovery port is connected to the outside through the third channel 503 to balance the pressure inside cavity 2. When riboflavin solution or saline solution is withdrawn from cavity 2 through recovery port, injection port 6 is connected to the outside through the first channel 501 to balance the pressure inside cavity 2. The injection port 6 and recovery port are connected to the outside alternately, which ensures that the pressure inside cavity 2 is always maintained at a normal pressure, preventing damage to the posterior sclera 10.

[0061] Specifically, when riboflavin solution or saline solution needs to be injected, the recovery port is connected to the outside to balance the pressure inside and outside the treatment cavity; when the riboflavin absorption reaches the predetermined time, the recovery port is connected to the pump to extract excess riboflavin solution, and at this time the administration port is connected to the outside to balance the pressure inside and outside the treatment cavity; the subsequent flushing process with saline solution is similar to the above; then during the phototherapy phase, oxygen needs to be continuously applied to the cavity 2 through the administration port 6 to ensure the activity of the sclera.

[0062] In some embodiments, a shape memory alloy 8 is also covered at the drug delivery port 6, with one end of the shape memory alloy 8 fixed to the wall of the cavity 2 at the drug delivery port 6 and the other end of the shape memory alloy 8 being a free end.

[0063] When the light provided by, for example, an optical fiber is extinguished, the shape memory alloy 8 undergoes thermal deformation and bends toward the radial center of the first opening 201 of the cavity 2, so as not to block the drug delivery port 6, so that the drug delivery port 6 can deliver substances to the cavity 2.

[0064] When light, such as that provided by an optical fiber, is applied, the shape memory alloy 8 undergoes thermal deformation, its temperature decreases, and it returns to its original shape, covering the drug application port 6. This allows the shape memory alloy 8 to seal the drug application port 6, preventing any remaining material in the first channel 501 from entering the cavity 2 and affecting the illumination.

[0065] Specifically, such as Figure 6 As shown, the shape memory alloy 8, which completely covers the drug delivery section, controls the activation of the control circuit 9 when all optical fibers are turned off. One end of the shape memory material is fixed, and the other end is free. When the control circuit 9 is activated to form a loop (when all optical fibers are turned off), the shape memory alloy 8 (or the resistance wire placed nearby) heats up, causing it to undergo thermal deformation and bend towards the radial center of the treatment cavity port, thereby opening the drug delivery section. Conversely, when the control circuit 9 is deactivated (when any optical fiber is lit), the control circuit 9 is deactivated, causing the shape memory alloy 8 to cool down, restore its original shape, and seal the drug delivery section, preventing residual riboflavin solution or other substances in the first channel 501 (i.e., the drug delivery pipe) from flowing into the treatment cavity and affecting the illumination.

[0066] The "substance" mentioned in this embodiment refers to a substance that can enter the cavity of the scleral cross-linking device to treat and assist in the treatment of the sclera, including but not limited to dissolved oxygen riboflavin solution, physiological saline and oxygen.

[0067] The method of using the scleral crosslinking device in this embodiment includes the following steps:

[0068] Step 1: Insert the device body between the eye socket and the eyeball, and adjust it so that the center of the reflective part is aligned with the treatment position of the posterior sclera 10; inflate the annular sealing ring 4 to make it expand, so that the contact surface 1 of the device body is attached to the posterior sclera 10, and the scleral cross-linking device is fixed between the posterior sclera 10 and the tissue behind the posterior sclera 10.

[0069] Step 2: Riboflavin, for example, is introduced into cavity 2 through the first channel 501.

[0070] Step 3: Light is guided onto the reflective part through the second channel 502 and then refracted onto the posterior sclera 10.

[0071] Step 4: Stop irradiating with light, release the gas from the annular sealing ring 4 through the fourth channel 504 until the device body separates from the posterior sclera 10, and then remove the device body.

[0072] It should be noted that the components or steps in the above embodiments can be interchanged, substituted, added, or deleted. Therefore, the combinations formed by these reasonable permutations and transformations should also fall within the protection scope of this utility model, and the protection scope of this utility model should not be limited to the above embodiments.

[0073] The above are exemplary embodiments disclosed in this utility model. The order of the disclosed embodiments is merely for descriptive purposes and does not represent the superiority or inferiority of the embodiments. However, it should be noted that the discussion of any of the above embodiments is merely exemplary and is not intended to imply that the scope of the disclosed embodiments of this utility model (including the claims) is limited to these examples. Various changes and modifications can be made without departing from the scope defined by the claims. The functions, steps, and / or actions of the methods according to the disclosed embodiments described herein do not need to be performed in any particular order. Furthermore, although the elements disclosed in the embodiments of this utility model may be described or claimed individually, they may be understood as multiple unless explicitly limited to a singular number.

[0074] Those skilled in the art should understand that the discussion of any of the above embodiments is merely exemplary and is not intended to imply that the scope of the present invention (including the claims) is limited to these examples. Within the framework of the present invention, technical features of the above embodiments or different embodiments can also be combined, and many other variations of different aspects of the present invention as described above exist, which are not provided in the details for the sake of brevity. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A self-sealing scleral cross-linking device, characterized by, The device comprises: a device body comprising a contact surface for contacting the posterior sclera, the contact surface being an inwardly curved arcuate surface; the device body comprises a cavity with two open ends, a first opening of the cavity being located on the contact surface; a second opening of the cavity is provided with a light-reflecting part, the light-reflecting part, the cavity and the posterior sclera enclosing a closed treatment cavity; a cross-linking substance enters the treatment cavity through the device body to cross-link with the posterior sclera; the first opening of the cavity is provided with an inflatable annular sealing ring on the contact surface, the annular sealing ring being used to contact the posterior sclera and to expand when inflated to fix the sclera cross-linking device between the posterior sclera and the tissue behind the posterior sclera.

2. The self-sealing scleral cross-linking device of claim 1, wherein, The device body further comprises an extension extending from the contact surface, the extension being provided with a first channel, a second channel, a third channel and a fourth channel in communication with the cavity; wherein the fourth channel is in communication with the annular sealing ring for inflating or deflating the annular sealing ring.

3. The self-sealing scleral cross-linking device of claim 2, wherein, The sclera cross-linking device further comprises: a drug delivery port and a recovery port provided on the inner side of the cavity, the recovery port being located at the lowest point of the liquid surface in the cavity after the sclera cross-linking device is fixed to the posterior sclera; the drug delivery port and the recovery port are oppositely arranged; the first channel is in airtight communication with the drug delivery port for introducing a substance into the cavity; the second channel is used to introduce light into the light-reflecting part; the third channel is in airtight communication with the recovery port for discharging the substance in the cavity.

4. The self-sealing scleral cross-linking device of claim 1, wherein, The annular sealing ring is a hollow structure made of elastic material.

5. The self-sealing scleral cross-linking device of claim 4, wherein, The annular sealing ring is a hollow structure in the shape of a circular tube.

6. The self-sealing scleral cross-linking device of claim 4, wherein, The annular sealing ring comprises a first annular surface for contacting the posterior sclera, a second annular surface fixed to the contact surface, and two side surfaces connecting the first annular surface and the second annular surface, the first annular surface, the second annular surface and the two side surfaces forming a hollow structure; the first annular surface is a smooth surface, and the two side surfaces are crumpled surfaces that can be compressed and expanded.

7. The self-sealing scleral cross-linking device of claim 3, wherein, The shape of the drug delivery port on the inner side wall of the cavity is selected from any one of a circular hole, an elliptical hole or a long strip-shaped opening; the drug delivery port is in communication with the first channel, the other end of the first channel being capable of being in communication with a delivery device or the outside world for applying the substance to the cavity and balancing the air pressure in the cavity with the outside world, the substance including at least one of the cross-linking substance and physiological saline, the cross-linking substance including at least one of a riboflavin solution with dissolved oxygen and oxygen.

8. The self-sealing scleral cross-linking device of claim 3, wherein, The shape of the recovery port is selected from any one of a circular hole, an elliptical hole or a long strip-shaped opening; the recovery port is in communication with the third channel, the other end of the third channel being capable of being in communication with a pump or the outside world for pumping out excess substance in the cavity and balancing the air pressure in the cavity with the outside world, the substance including at least one of the cross-linking substance and physiological saline, the cross-linking substance including at least one of a riboflavin solution with dissolved oxygen and oxygen.

9. The self-sealing scleral cross-linking device of claim 7 or 8, wherein, When the riboflavin solution or physiological saline is injected into the cavity through the administration port, the recovery port is communicated with the outside through the third channel to balance the pressure in the cavity; when the riboflavin solution or physiological saline is extracted from the cavity through the recovery port, the administration port is communicated with the outside through the first channel to balance the pressure in the cavity.

10. The self-sealing scleral cross-linking device of claim 3, wherein, The administration port is also covered with a memory alloy, one end of the memory alloy is fixed on the wall of the cavity at the administration port, and the other end of the memory alloy is a free end. When the light is off, the memory alloy is heat-deformed and bent towards the radial center of the first opening of the cavity, so as not to block the administration port, so that the administration port can deliver substances to the cavity; When the light is on, the heat-deformed memory alloy is cooled and returns to the original shape and covers the administration port, so that the memory alloy blocks the administration port to prevent the remaining substances in the first channel from entering the cavity and affecting the light.

Images